JP4417424B2 - 発がん抑制剤 - Google Patents
発がん抑制剤 Download PDFInfo
- Publication number
- JP4417424B2 JP4417424B2 JP2008517764A JP2008517764A JP4417424B2 JP 4417424 B2 JP4417424 B2 JP 4417424B2 JP 2008517764 A JP2008517764 A JP 2008517764A JP 2008517764 A JP2008517764 A JP 2008517764A JP 4417424 B2 JP4417424 B2 JP 4417424B2
- Authority
- JP
- Japan
- Prior art keywords
- propanedioic acid
- group
- naphthalenyl
- oxy
- pentyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003112 inhibitor Substances 0.000 title description 2
- 230000000711 cancerogenic effect Effects 0.000 title 1
- 231100000315 carcinogenic Toxicity 0.000 title 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 43
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 208000030399 gastrointestinal polyp Diseases 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 13
- 231100000252 nontoxic Toxicity 0.000 claims description 9
- 230000003000 nontoxic effect Effects 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 230000000069 prophylactic effect Effects 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- FTSCFVVSJVAFEZ-UHFFFAOYSA-N 2-[5-[6-(5-tert-butyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=C(OCCCCCC(C(O)=O)C(O)=O)C=CC2=CC(C=3OC4=CC=C(C=C4N=3)C(C)(C)C)=CC=C21 FTSCFVVSJVAFEZ-UHFFFAOYSA-N 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 description 29
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 26
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 20
- 230000003449 preventive effect Effects 0.000 description 17
- -1 specifically Chemical group 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 206010027476 Metastases Diseases 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000009401 metastasis Effects 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 235000013772 propylene glycol Nutrition 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 208000037062 Polyps Diseases 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002429 large intestine Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000005623 Carcinogenesis Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 208000032177 Intestinal Polyps Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000036952 cancer formation Effects 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- ALTNQULKZCSDFR-UHFFFAOYSA-N 2-[3-[6-[4-[(2-fluorophenyl)methoxy]-6-phenylpyrimidin-2-yl]naphthalen-2-yl]oxypropyl]propanedioic acid Chemical compound C1=CC2=CC(OCCCC(C(=O)O)C(O)=O)=CC=C2C=C1C(N=C(C=1)C=2C=CC=CC=2)=NC=1OCC1=CC=CC=C1F ALTNQULKZCSDFR-UHFFFAOYSA-N 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- HWRVQKHBHAMOER-UHFFFAOYSA-N 2-[3-[6-(1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypropyl]propanedioic acid Chemical compound C1=CC=C2OC(C3=CC4=CC=C(C=C4C=C3)OCCCC(C(=O)O)C(O)=O)=NC2=C1 HWRVQKHBHAMOER-UHFFFAOYSA-N 0.000 description 2
- 101150071279 Apc gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- VWYDTEVMGAMQGM-UHFFFAOYSA-N diethyl 2-[3-[6-(1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypropyl]propanedioate Chemical compound C1=CC=C2OC(C3=CC4=CC=C(C=C4C=C3)OCCCC(C(=O)OCC)C(=O)OCC)=NC2=C1 VWYDTEVMGAMQGM-UHFFFAOYSA-N 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- ZNXAHODPBOMEPW-UHFFFAOYSA-N 2-[3-[3-(5-chloro-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypropyl]propanedioic acid Chemical compound ClC1=CC=C2OC(C3=CC4=CC=CC=C4C=C3OCCCC(C(=O)O)C(O)=O)=NC2=C1 ZNXAHODPBOMEPW-UHFFFAOYSA-N 0.000 description 1
- RNJCCFOCIXBBRV-UHFFFAOYSA-N 2-[3-[5-(5-tert-butyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypropyl]propanedioic acid Chemical compound OC(=O)C(C(O)=O)CCCOC1=CC=C2C(C=3OC4=CC=C(C=C4N=3)C(C)(C)C)=CC=CC2=C1 RNJCCFOCIXBBRV-UHFFFAOYSA-N 0.000 description 1
- QWKYUIKUMNUKOZ-UHFFFAOYSA-N 2-[3-[6-(1,3-benzothiazol-2-yl)naphthalen-2-yl]oxypropyl]propanedioic acid Chemical compound C1=CC=C2SC(C3=CC4=CC=C(C=C4C=C3)OCCCC(C(=O)O)C(O)=O)=NC2=C1 QWKYUIKUMNUKOZ-UHFFFAOYSA-N 0.000 description 1
- BHHZZQAKETZCGM-UHFFFAOYSA-N 2-[3-[6-(4-methyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypropyl]propanedioic acid Chemical compound C1=C(OCCCC(C(O)=O)C(O)=O)C=CC2=CC(C=3OC=4C=CC=C(C=4N=3)C)=CC=C21 BHHZZQAKETZCGM-UHFFFAOYSA-N 0.000 description 1
- FFBGNEORJHPPDQ-UHFFFAOYSA-N 2-[3-[6-(5-chloro-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypropyl]propanedioic acid Chemical compound ClC1=CC=C2OC(C3=CC4=CC=C(C=C4C=C3)OCCCC(C(=O)O)C(O)=O)=NC2=C1 FFBGNEORJHPPDQ-UHFFFAOYSA-N 0.000 description 1
- PASKQRYKPCVCRN-UHFFFAOYSA-N 2-[3-[6-(5-phenyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypropyl]propanedioic acid Chemical compound C1=CC2=CC(OCCCC(C(=O)O)C(O)=O)=CC=C2C=C1C(OC1=CC=2)=NC1=CC=2C1=CC=CC=C1 PASKQRYKPCVCRN-UHFFFAOYSA-N 0.000 description 1
- VSGXZFRNPWXTOQ-UHFFFAOYSA-N 2-[3-[6-[4-[(2-fluorophenyl)methoxy]-6-(4-methoxyphenyl)pyrimidin-2-yl]naphthalen-2-yl]oxypropyl]propanedioic acid Chemical compound C1=CC(OC)=CC=C1C1=CC(OCC=2C(=CC=CC=2)F)=NC(C=2C=C3C=CC(OCCCC(C(O)=O)C(O)=O)=CC3=CC=2)=N1 VSGXZFRNPWXTOQ-UHFFFAOYSA-N 0.000 description 1
- NRDUBXALTDXRGX-UHFFFAOYSA-N 2-[5-[3-(5-chloro-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound ClC1=CC=C2OC(C3=CC4=CC=CC=C4C=C3OCCCCCC(C(=O)O)C(O)=O)=NC2=C1 NRDUBXALTDXRGX-UHFFFAOYSA-N 0.000 description 1
- NXKLPNTUQATRQM-UHFFFAOYSA-N 2-[5-[3-(5-phenyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound OC(=O)C(C(O)=O)CCCCCOC1=CC2=CC=CC=C2C=C1C(OC1=CC=2)=NC1=CC=2C1=CC=CC=C1 NXKLPNTUQATRQM-UHFFFAOYSA-N 0.000 description 1
- RDEJOABGEZJKKE-UHFFFAOYSA-N 2-[5-[3-(5-tert-butyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=CC=C2C=C(OCCCCCC(C(O)=O)C(O)=O)C(C=3OC4=CC=C(C=C4N=3)C(C)(C)C)=CC2=C1 RDEJOABGEZJKKE-UHFFFAOYSA-N 0.000 description 1
- NKGUMHPAWGOIKI-UHFFFAOYSA-N 2-[5-[3-(6-methyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=CC=C2C=C(OCCCCCC(C(O)=O)C(O)=O)C(C3=NC4=CC=C(C=C4O3)C)=CC2=C1 NKGUMHPAWGOIKI-UHFFFAOYSA-N 0.000 description 1
- PUEUXRJEXCGTAB-UHFFFAOYSA-N 2-[5-[5-(5-phenyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C=1C=CC2=CC(OCCCCCC(C(=O)O)C(O)=O)=CC=C2C=1C(OC1=CC=2)=NC1=CC=2C1=CC=CC=C1 PUEUXRJEXCGTAB-UHFFFAOYSA-N 0.000 description 1
- YTTGZSSBUIDLSN-UHFFFAOYSA-N 2-[5-[5-(5-tert-butyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound OC(=O)C(C(O)=O)CCCCCOC1=CC=C2C(C=3OC4=CC=C(C=C4N=3)C(C)(C)C)=CC=CC2=C1 YTTGZSSBUIDLSN-UHFFFAOYSA-N 0.000 description 1
- KKDFPASCKRFEAA-UHFFFAOYSA-N 2-[5-[5-(6-methyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound OC(=O)C(C(O)=O)CCCCCOC1=CC=C2C(C3=NC4=CC=C(C=C4O3)C)=CC=CC2=C1 KKDFPASCKRFEAA-UHFFFAOYSA-N 0.000 description 1
- KJXTWTXBVPNTGP-UHFFFAOYSA-N 2-[5-[5-[6-(diethylamino)-1,3-benzoxazol-2-yl]naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound OC(=O)C(C(O)=O)CCCCCOC1=CC=C2C(C3=NC4=CC=C(C=C4O3)N(CC)CC)=CC=CC2=C1 KJXTWTXBVPNTGP-UHFFFAOYSA-N 0.000 description 1
- AQUFDELTQCKPQN-UHFFFAOYSA-N 2-[5-[6-(1,3-oxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=CC2=CC(OCCCCCC(C(=O)O)C(O)=O)=CC=C2C=C1C1=NC=CO1 AQUFDELTQCKPQN-UHFFFAOYSA-N 0.000 description 1
- QCHHBZOJEMSBBD-UHFFFAOYSA-N 2-[5-[6-(4,5-diphenyl-1,3-oxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=CC2=CC(OCCCCCC(C(=O)O)C(O)=O)=CC=C2C=C1C(O1)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 QCHHBZOJEMSBBD-UHFFFAOYSA-N 0.000 description 1
- MJAUKPYLGFFNJW-UHFFFAOYSA-N 2-[5-[6-(4-methyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=C(OCCCCCC(C(O)=O)C(O)=O)C=CC2=CC(C=3OC=4C=CC=C(C=4N=3)C)=CC=C21 MJAUKPYLGFFNJW-UHFFFAOYSA-N 0.000 description 1
- TUUZZFQJVPSKIK-UHFFFAOYSA-N 2-[5-[6-(4-oxo-6-phenyl-1h-pyrimidin-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=CC2=CC(OCCCCCC(C(=O)O)C(O)=O)=CC=C2C=C1C(N1)=NC(=O)C=C1C1=CC=CC=C1 TUUZZFQJVPSKIK-UHFFFAOYSA-N 0.000 description 1
- PLGGPPRMYXTWLZ-UHFFFAOYSA-N 2-[5-[6-(4-phenyl-6-phenylmethoxypyrimidin-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=CC2=CC(OCCCCCC(C(=O)O)C(O)=O)=CC=C2C=C1C(N=C(C=1)C=2C=CC=CC=2)=NC=1OCC1=CC=CC=C1 PLGGPPRMYXTWLZ-UHFFFAOYSA-N 0.000 description 1
- HUJNPJLXYWNFII-UHFFFAOYSA-N 2-[5-[6-(4-tert-butyl-1,3-oxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound CC(C)(C)C1=COC(C=2C=C3C=CC(OCCCCCC(C(O)=O)C(O)=O)=CC3=CC=2)=N1 HUJNPJLXYWNFII-UHFFFAOYSA-N 0.000 description 1
- XSRWMNYOYIECAJ-UHFFFAOYSA-N 2-[5-[6-(5-chloro-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound ClC1=CC=C2OC(C3=CC4=CC=C(C=C4C=C3)OCCCCCC(C(=O)O)C(O)=O)=NC2=C1 XSRWMNYOYIECAJ-UHFFFAOYSA-N 0.000 description 1
- CKZVUERNPLYZOG-UHFFFAOYSA-N 2-[5-[6-(6-methoxy-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=C(OCCCCCC(C(O)=O)C(O)=O)C=CC2=CC(C3=NC4=CC=C(C=C4O3)OC)=CC=C21 CKZVUERNPLYZOG-UHFFFAOYSA-N 0.000 description 1
- DXCFDIRHZPNOTB-UHFFFAOYSA-N 2-[5-[6-(6-methyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=C(OCCCCCC(C(O)=O)C(O)=O)C=CC2=CC(C3=NC4=CC=C(C=C4O3)C)=CC=C21 DXCFDIRHZPNOTB-UHFFFAOYSA-N 0.000 description 1
- DSLYUBLFMYEFAX-UHFFFAOYSA-N 2-[5-[6-(6-phenylmethoxy-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=CC2=CC(OCCCCCC(C(=O)O)C(O)=O)=CC=C2C=C1C(OC1=C2)=NC1=CC=C2OCC1=CC=CC=C1 DSLYUBLFMYEFAX-UHFFFAOYSA-N 0.000 description 1
- OHZFPYITRBBURA-UHFFFAOYSA-N 2-[5-[6-[4,5-bis(4-methoxyphenyl)-1,3-oxazol-2-yl]naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)OC(C=2C=C3C=CC(OCCCCCC(C(O)=O)C(O)=O)=CC3=CC=2)=N1 OHZFPYITRBBURA-UHFFFAOYSA-N 0.000 description 1
- GXGRVEIGBDVFOG-UHFFFAOYSA-N 2-[5-[6-[4,5-bis(4-methylphenyl)-1,3-oxazol-2-yl]naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=CC(C)=CC=C1C1=C(C=2C=CC(C)=CC=2)OC(C=2C=C3C=CC(OCCCCCC(C(O)=O)C(O)=O)=CC3=CC=2)=N1 GXGRVEIGBDVFOG-UHFFFAOYSA-N 0.000 description 1
- FIALYNHXOGWPRR-UHFFFAOYSA-N 2-[5-[6-[4-oxo-6-(trifluoromethyl)-1h-pyrimidin-2-yl]naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=CC2=CC(OCCCCCC(C(=O)O)C(O)=O)=CC=C2C=C1C1=NC(=O)C=C(C(F)(F)F)N1 FIALYNHXOGWPRR-UHFFFAOYSA-N 0.000 description 1
- BRMGYTCJIOBRLK-UHFFFAOYSA-N 2-[5-[6-[4-tert-butyl-6-(cyclohexylmethoxy)pyrimidin-2-yl]naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound N=1C(C=2C=C3C=CC(OCCCCCC(C(O)=O)C(O)=O)=CC3=CC=2)=NC(C(C)(C)C)=CC=1OCC1CCCCC1 BRMGYTCJIOBRLK-UHFFFAOYSA-N 0.000 description 1
- NJKQHWWBLZZNNI-UHFFFAOYSA-N 2-[5-[6-[4-tert-butyl-6-[(2-chlorophenyl)methoxy]pyrimidin-2-yl]naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound N=1C(C=2C=C3C=CC(OCCCCCC(C(O)=O)C(O)=O)=CC3=CC=2)=NC(C(C)(C)C)=CC=1OCC1=CC=CC=C1Cl NJKQHWWBLZZNNI-UHFFFAOYSA-N 0.000 description 1
- BUOSYGOUXIOTMH-UHFFFAOYSA-N 2-[5-[6-[4-tert-butyl-6-[(4-fluorophenyl)methoxy]pyrimidin-2-yl]naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound N=1C(C=2C=C3C=CC(OCCCCCC(C(O)=O)C(O)=O)=CC3=CC=2)=NC(C(C)(C)C)=CC=1OCC1=CC=C(F)C=C1 BUOSYGOUXIOTMH-UHFFFAOYSA-N 0.000 description 1
- RRAGFNKJCZPFMN-UHFFFAOYSA-N 2-[5-[6-[6-(cyclohexylmethoxy)-1,3-benzoxazol-2-yl]naphthalen-2-yl]oxypentyl]propanedioic acid Chemical compound C1=CC2=CC(OCCCCCC(C(=O)O)C(O)=O)=CC=C2C=C1C(OC1=C2)=NC1=CC=C2OCC1CCCCC1 RRAGFNKJCZPFMN-UHFFFAOYSA-N 0.000 description 1
- JSHPQGPCSWMQEV-UHFFFAOYSA-N 2-ethoxycarbonyl-7-[6-(4-phenyl-6-phenylmethoxypyrimidin-2-yl)naphthalen-2-yl]oxyheptanoic acid Chemical compound C1=CC2=CC(OCCCCCC(C(=O)OCC)C(O)=O)=CC=C2C=C1C(N=C(C=1)C=2C=CC=CC=2)=NC=1OCC1=CC=CC=C1 JSHPQGPCSWMQEV-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- HYTYUXVPOUPXGI-UHFFFAOYSA-N 6-(1,3-benzoxazol-2-yl)naphthalen-2-ol Chemical compound C1=CC=C2OC(C3=CC4=CC=C(C=C4C=C3)O)=NC2=C1 HYTYUXVPOUPXGI-UHFFFAOYSA-N 0.000 description 1
- MWTHCHYHDDXSPJ-UHFFFAOYSA-N 6-[4-[(2-fluorophenyl)methoxy]-6-phenylpyrimidin-2-yl]naphthalen-2-ol Chemical compound C1=CC2=CC(O)=CC=C2C=C1C(N=C(C=1)C=2C=CC=CC=2)=NC=1OCC1=CC=CC=C1F MWTHCHYHDDXSPJ-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102000000763 Survivin Human genes 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- LQEJKDNALLXRCT-UHFFFAOYSA-N chloroform;toluene Chemical compound ClC(Cl)Cl.CC1=CC=CC=C1 LQEJKDNALLXRCT-UHFFFAOYSA-N 0.000 description 1
- 230000004736 colon carcinogenesis Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000004732 colorectal carcinogenesis Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- WUOPYKKJFZHTRA-UHFFFAOYSA-N diethyl 2-(3-chloropropyl)propanedioate Chemical compound CCOC(=O)C(CCCCl)C(=O)OCC WUOPYKKJFZHTRA-UHFFFAOYSA-N 0.000 description 1
- ZWTYCIFQXOFBRV-UHFFFAOYSA-N diethyl 2-[3-[5-(5-chloro-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypropyl]propanedioate Chemical compound ClC1=CC=C2OC(C=3C4=CC=C(C=C4C=CC=3)OCCCC(C(=O)OCC)C(=O)OCC)=NC2=C1 ZWTYCIFQXOFBRV-UHFFFAOYSA-N 0.000 description 1
- NWLPOPKBDTWTQI-UHFFFAOYSA-N diethyl 2-[3-[6-(5-phenyl-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypropyl]propanedioate Chemical compound C1=CC2=CC(OCCCC(C(=O)OCC)C(=O)OCC)=CC=C2C=C1C(OC1=CC=2)=NC1=CC=2C1=CC=CC=C1 NWLPOPKBDTWTQI-UHFFFAOYSA-N 0.000 description 1
- JWXKKCAQHQNDDQ-UHFFFAOYSA-N diethyl 2-[3-[6-[4-[(2-fluorophenyl)methoxy]-6-phenylpyrimidin-2-yl]naphthalen-2-yl]oxypropyl]propanedioate Chemical compound C1=CC2=CC(OCCCC(C(=O)OCC)C(=O)OCC)=CC=C2C=C1C(N=C(C=1)C=2C=CC=CC=2)=NC=1OCC1=CC=CC=C1F JWXKKCAQHQNDDQ-UHFFFAOYSA-N 0.000 description 1
- REZMZBHJAQUYDM-UHFFFAOYSA-N diethyl 2-[5-[3-(6-nitro-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioate Chemical compound C1=C([N+]([O-])=O)C=C2OC(C3=CC4=CC=CC=C4C=C3OCCCCCC(C(=O)OCC)C(=O)OCC)=NC2=C1 REZMZBHJAQUYDM-UHFFFAOYSA-N 0.000 description 1
- SULXOMIZCZKNKY-UHFFFAOYSA-N diethyl 2-[5-[5-(5-chloro-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioate Chemical compound ClC1=CC=C2OC(C=3C4=CC=C(C=C4C=CC=3)OCCCCCC(C(=O)OCC)C(=O)OCC)=NC2=C1 SULXOMIZCZKNKY-UHFFFAOYSA-N 0.000 description 1
- NFWBATIBBKQRMM-UHFFFAOYSA-N diethyl 2-[5-[5-(6-nitro-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioate Chemical compound C1=C([N+]([O-])=O)C=C2OC(C=3C4=CC=C(C=C4C=CC=3)OCCCCCC(C(=O)OCC)C(=O)OCC)=NC2=C1 NFWBATIBBKQRMM-UHFFFAOYSA-N 0.000 description 1
- OFPSTALTUOLKRJ-UHFFFAOYSA-N diethyl 2-[5-[5-[6-(cyclohexylmethoxy)-1,3-benzoxazol-2-yl]naphthalen-2-yl]oxypentyl]propanedioate Chemical compound C=1C=CC2=CC(OCCCCCC(C(=O)OCC)C(=O)OCC)=CC=C2C=1C(OC1=C2)=NC1=CC=C2OCC1CCCCC1 OFPSTALTUOLKRJ-UHFFFAOYSA-N 0.000 description 1
- JWGNMNNMNSNQLE-UHFFFAOYSA-N diethyl 2-[5-[6-(1,3-benzothiazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioate Chemical compound C1=CC=C2SC(C3=CC4=CC=C(C=C4C=C3)OCCCCCC(C(=O)OCC)C(=O)OCC)=NC2=C1 JWGNMNNMNSNQLE-UHFFFAOYSA-N 0.000 description 1
- ITZHTMZARNUTAB-UHFFFAOYSA-N diethyl 2-[5-[6-(4,5-dimethyl-1,3-oxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioate Chemical compound C1=CC2=CC(OCCCCCC(C(=O)OCC)C(=O)OCC)=CC=C2C=C1C1=NC(C)=C(C)O1 ITZHTMZARNUTAB-UHFFFAOYSA-N 0.000 description 1
- OIMIVGLQWRKLGY-UHFFFAOYSA-N diethyl 2-[5-[6-(5-phenyl-1,3-oxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioate Chemical compound C1=CC2=CC(OCCCCCC(C(=O)OCC)C(=O)OCC)=CC=C2C=C1C(O1)=NC=C1C1=CC=CC=C1 OIMIVGLQWRKLGY-UHFFFAOYSA-N 0.000 description 1
- BNXLJNQYTZALRD-UHFFFAOYSA-N diethyl 2-[5-[6-(6-methoxy-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioate Chemical compound C1=C(OC)C=C2OC(C3=CC4=CC=C(C=C4C=C3)OCCCCCC(C(=O)OCC)C(=O)OCC)=NC2=C1 BNXLJNQYTZALRD-UHFFFAOYSA-N 0.000 description 1
- YHGNWDIRSMAYIM-UHFFFAOYSA-N diethyl 2-[5-[6-(6-nitro-1,3-benzoxazol-2-yl)naphthalen-2-yl]oxypentyl]propanedioate Chemical compound C1=C([N+]([O-])=O)C=C2OC(C3=CC4=CC=C(C=C4C=C3)OCCCCCC(C(=O)OCC)C(=O)OCC)=NC2=C1 YHGNWDIRSMAYIM-UHFFFAOYSA-N 0.000 description 1
- JMABAHBJFWASAI-UHFFFAOYSA-N diethyl 2-[5-[6-[4,5-bis(4-methoxyphenyl)-1,3-oxazol-2-yl]naphthalen-2-yl]oxypentyl]propanedioate Chemical compound C1=CC2=CC(OCCCCCC(C(=O)OCC)C(=O)OCC)=CC=C2C=C1C(O1)=NC(C=2C=CC(OC)=CC=2)=C1C1=CC=C(OC)C=C1 JMABAHBJFWASAI-UHFFFAOYSA-N 0.000 description 1
- VMLXMYGJKXDJAY-UHFFFAOYSA-N diethyl 2-[5-[6-[4-(4-chlorophenyl)-1,3-oxazol-2-yl]naphthalen-2-yl]oxypentyl]propanedioate Chemical compound C1=CC2=CC(OCCCCCC(C(=O)OCC)C(=O)OCC)=CC=C2C=C1C(OC=1)=NC=1C1=CC=C(Cl)C=C1 VMLXMYGJKXDJAY-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- UBXZGICQTXLNRL-UHFFFAOYSA-L disodium;2-[5-[6-[6-(diethylamino)-1,3-benzoxazol-2-yl]naphthalen-2-yl]oxypentyl]propanedioate Chemical compound [Na+].[Na+].C1=C(OCCCCCC(C([O-])=O)C([O-])=O)C=CC2=CC(C3=NC4=CC=C(C=C4O3)N(CC)CC)=CC=C21 UBXZGICQTXLNRL-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000019860 lauric fat Nutrition 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
また、シクロオキシゲナーゼ−2(COX−2)の選択的阻害剤を用いた大腸がんの治療薬としての研究では、実験動物の腸発がんを抑制することが報告されており(非特許文献1)、いずれも副作用の少ない化学療法薬として期待されていた。
しかしながら、分子標的薬の非小細胞肺がん治療薬の副作用による間質性肺炎の発症や、COX−2阻害剤の投与による高い心血管リスクの発生等、副作用による薬害によって使用が制限される薬剤も多く、安全性、有効性の高い抗悪性腫瘍薬の開発が待たれている。
近年、主に肥大化した脂肪細胞から放出される生理活性物質であるアデイポサイトカインが、糖尿病やメタボリック症候群のみならず、発がんにも深く関与していることが報告されている。発がんに関連すると報告のあるアデイポサイトカインとしては、プラスミノーゲン アクチベーター インヒビター−1(PAI−1)、アデイポネクチン、TNF、レプチンが挙げられる。
他方、PAI−1阻害活性作用を有するプロパン二酸誘導体については、特許文献4、特許文献5及び特許文献6において開示されている。しかしながら、特許文献4、特許文献5及び特許文献6におけるPAI−1阻害活性化合物の用途は、血栓溶解剤又は抗血栓剤に関するものであり、これらのプロパン二酸誘導体が、悪性腫瘍の予防や治療薬として、また悪性腫瘍の転移予防薬として有効であるかどうかは未だ全く検討されていない。
〔式(1)において、環Aは、オキサゾール、ベンゾオキサゾール、ベンゾチアゾール又はピリミジンを表し;R1は、水酸基、アルキル基、低級アルコキシ基、シクロヘキシルメトキシ基、ベンジルオキシ基(ここで、ベンジルオキシ基のフェニルは、低級アルキル基、低級アルコキシ基及びハロゲン原子から選ばれる置換基で置換されていてもよい。)、トリフルオロメチル基、ニトロ基、−N(R4、R5)基(ここで、R4、R5は、それぞれ独立して水素原子、アルキル基又はベンジル基を意味する。)、ハロゲン原子、フェニル基(ここで、フェニル基は低級アルキル基、低級アルコキシ基およびハロゲン原子から選ばれる置換基で置換されていてもよい。)を表し;R2及びR3は、それぞれ独立して水素原子又は低級アルキル基を表し;mは、0又は1から4の整数を表し、m個のR1は、それぞれ同一又は異なってもよく;Wは、3から5の整数を表す。〕
で表されるプロパン二酸誘導体、その非毒性塩、溶媒和物、又はそれらのプロドラック体を有効成分として含有する消化管ポリープ及び/又は悪性腫瘍の予防もしくは治療薬、又は悪性腫瘍の転移予防薬に関する。
更に、本発明は、消化管ポリープ及び/又は悪性腫瘍の予防もしくは治療薬、又は悪性腫瘍の転移予防薬を製造する為の式(1)で表されるプロパン二酸誘導体、その非毒性塩、溶媒和物、又はそれらのプロドラック体の使用に関する。
更に、本発明は、式(1)で表されるプロパン二酸誘導体、その非毒性塩、溶媒和物、又はそれらのプロドラック体をヒト又は動物に投与する事からなる、消化管ポリープ及び/又は悪性腫瘍を予防もしくは治療する、又は悪性腫瘍の転移を予防する方法に関する。
「低級アルコキシ基」とは、炭素数1〜4個の直鎖又は分岐状のアルコキシ基を意味し、具体的にはメトキシ基、エトキシ基、プロポキシ基、イソプロポキシ基、ブトキシ基、イソブトキシ基、sec-ブトキシ基、tert-ブトキシ基等が挙げられる。好ましくはメトキシ基、エトキシ基である。
「ハロゲン原子」とは、具体的には塩素原子、臭素原子、フッ素原子である。
〔式(2)において、R2、R3及びWは前記の意味を表し、R6及びR7は、それぞれ同一又は異なって、水素原子、アルキル基、フェニル基(ここで、フェニル基は低級アルキル基、低級アルコキシ基及びハロゲン原子から選ばれる置換基で置換されていてもよい。)を表す。〕
で表されるプロパン二酸誘導体が好ましい。このようなプロパン二酸誘導体の好ましい具体的化合物としては、例えば、以下の化合物が挙げられる。
[5−[[6−(2−オキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−(4,5−ジメチル−2−オキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸ジエチルエステル、
[5−[[6−[4−(1,1−ジメチルエチル)−2−オキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−(5−フェニル−2−オキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸ジエチルエステル、
[5−[[6−[4−(4−クロロフェニル)−2−オキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸ジエチルエステル、
[5−[[6−(4,5−ジフェニル−2−オキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−[4,5−ビス(4−メチルフェニル)−2−オキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−[4,5−ビス(4−メトキシフェニル)−2−オキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸ジエチルエステル、
[5−[[6−[4,5−ビス(4−メトキシフェニル)−2−オキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸。
〔式(3)において、Yは酸素原子又は硫黄原子を表し、R1、R2、R3、m及びWは前記の意味を表す。〕
で表されるプロパン二酸誘導体が好ましい。このようなプロパン二酸誘導体のなかでも、更に、環Aがベンゾオキサゾールである、下記式(4)
〔式(4)において、R2及びR3は前記の意味を表し、R8は、アルキル基を表す。〕
で表されるプロパン二酸誘導体が好ましい。特に、下記式(5)
〔式(5)において、R2及びR3は前記の意味を表す。〕で表されるプロパン二酸誘導体が好ましい。
[3−[[6−(2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]プロピル]プロパン二酸、
[3−[[6−(4−メチル−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]プロピル]プロパン二酸、
[3−[[6−(5−フェニル−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]プロピル]プロパン二酸ジエチルエステル、
[3−[[6−(5−フェニル−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]プロピル]プロパン二酸、
[3−[[6−(5−クロロ−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]プロピル]プロパン二酸、
[3−[[3−(5−クロロ−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]プロピル]プロパン二酸、
[3−[[5−[5−(1,1−ジメチルエチル)−2−ベンゾオキサゾリル]−2−ナフタレニル]オキシ]プロピル]プロパン二酸、
[3−[[5−(5−クロロ−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]プロピル]プロパン二酸ジエチルエステル、
[5−[[6−(4−メチル−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル] プロパン二酸、
[5−[[6−(6−メチル−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−[5−(1,1−ジメチルエチル)−2−ベンゾオキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−(6−メトキシ−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸ジエチルエステル、
[5−[[6−(6−メトキシ−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−[6−(シクロヘキシルメトキシ)−2−ベンゾオキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−[6−(フェニルメトキシ)−2−ベンゾオキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−(5−クロロ−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−(6−ニトロ−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸ジエチルエステル、
[5−[[6−[6−(ジエチルアミノ)−2−ベンゾオキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸二ナトリウム塩、
[5−[[3−(6−メチル−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[3−[5−(1,1−ジメチルエチル)−2−ベンゾオキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[3−(5−フェニル−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[3−(5−クロロ−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[3−(6−ニトロ−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸ジエチルエステル、
[5−[[5−(6−メチル−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[5−[5−(1,1−ジメチルエチル)−2−ベンゾオキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[5−[6−(シクロヘキシルメトキシ)−2−ベンゾオキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸ジエチルエステル、
[5−[[5−(5−フェニル−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[5−(5−クロロ−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸ジエチルエステル、
[5−[[5−(6−ニトロ−2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸ジエチルエステル、
[5−[[5−[6−(ジエチルアミノ)−2−ベンゾオキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸。
[3−[[6−(2−ベンゾチアゾリル)−2−ナフタレニル]オキシ]プロピル]プロパン二酸、
[5−[[6−(2−ベンゾチアゾリル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸ジエチルエステル。
〔式(6)において、R2、R3及びWは前記の意味を表し;R9は、水酸基、シクロヘキシルメトキシ基又はベンジルオキシ基(ここで、ベンジルオキシ基のフェニルは、低級アルキル基、低級アルコキシ基及びハロゲン原子から選ばれる置換基で置換されていてもよい。)を表し;R10は、アルキル基、トリフルオロメチル基、フェニル基(ここで、フェニル基は低級アルキル基、低級アルコキシ基及びハロゲン原子から選ばれる置換基で置換されていてもよい。)を表す。〕
で表されるプロパン二酸誘導体が好ましい。このようなプロパン二酸誘導体の好ましい具体的化合物としては、例えば、以下の化合物が挙げられる。
[3−[[6−[4−[(2−フルオロフェニル)メトキシ]−6−フェニル−2−ピリミジニル]−2−ナフタレニル]オキシ]プロピル]プロパン二酸、 [3−[[6−[4−[(2−フルオロフェニル)メトキシ]−6−(4−メトキシフェニル)−2−ピリミジニル]−2−ナフタレニル]オキシ]プロピル]プロパン二酸、
[5−[[6−[1,4−ジヒドロ−4−オキソ−6−(トリフルオロメチル)−2−ピリミジニル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−(1,4−ジヒドロ−4−オキソ−6−フェニル−2−ピリミジニル)−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−[4−フェニル−6−(フェニルメトキシ)−2−ピリミジニル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸エチルエステル、
[5−[[6−[4−フェニル−6−(フェニルメトキシ)−2−ピリミジニル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−[4−シクロヘキシルメトキシ−6−(1,1−ジメチルエチル)−2−ピリミジニル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、
[5−[[6−[4−(1,1−ジメチルエチル)−6−[(4−フルオロフェニル)メトキシ]−2−ピリミジニル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸、及び
[5−[[6−[4−[(2−クロロフェニル)メトキシ]−6−(1,1−ジメチルエチル)−2−ピリミジニル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸。
すなわち、本発明者らは、試験系として大腸がんの高危険群である家族性大腸腺腫症(FAP)のモデルマウス(Apc遺伝子ヘテロ欠損マウス)を用いた。このモデルマウスの特徴は2点ある。このマウスの血清トリグリセリド値が加齢とともに急激に上昇する事とWntシグナルの活性化により、多数のポリープが生成することである。そのため、このマウスは高脂血症状態と大腸発がんの関連性を調べる有用な動物実験モデルである。本試験では、FAP患者のポリープにおいてPAI−1発現が上昇していること、PAI−1はトリグリセリドによって発現誘導されることから、Apc遺伝子欠損マウスの一つであるMinマウスを用いてPAI−1阻害化合物の腸ポリープ生成抑制作用を評価した。このような試験系を実施することにより、本発明の式(1)から(6)で表されるプロパン二酸誘導体が、消化管ポリープ及び悪性腫瘍の発生を有意に抑制し、従って、消化管ポリープ及び/又は悪性腫瘍の予防もしくは治療薬、又は悪性腫瘍の転移予防薬として、極めて有効であることを見出した。
それらは単体で投与してもよいが、一般的には医薬組成物の形態で投与する。それらの製剤は薬理学的、製剤学的に許容し得る添加物を加え、常法により製造することができる。すなわち、経口剤には、通常の賦形剤、滑沢剤、結合剤、崩壊剤、湿潤剤、コーティング剤等の添加剤を用いることができる。経口用液剤は、水性又は油性懸濁液、溶液、乳濁液、シロップ、エリキシル等の形態であっても良く、あるいは使用前水又は他の適当な溶媒で調製するドライシロップとして供されてもよい。前記の液剤は、懸濁化剤、香料、希釈剤あるいは乳化剤のような通常の添加剤を含有できる。直腸内投与する場合は、坐剤として投与することができる。坐剤は、カカオ脂、ラウリン脂、マクロゴール、グリセロゼラチン、ウィテップゾール、ステアリン酸ナトリウム又はそれらの混合物など、適当な物質を基剤とし、必要に応じて乳化剤、懸濁化剤、保存剤等を加えることができる。注射剤は、水性あるいは用時溶解型剤形を構成し得る注射用蒸留水、生理食塩水、5%ブドウ糖溶液、プロピレングリコール等の溶解剤ないし溶解補助剤、pH調節剤、等張化剤、安定化剤等の製剤成分が使用される。上記組成物で用いられる賦形剤等の具体例を以下に挙げる。
[3−[[6−(2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]プロピル]プロパン二酸の製造:
6−(2−ベンゾオキサゾリル)−2−ナフタレノール(372mg)をDMF(15mL)に溶解し、炭酸カリウム(1.0g)、(3−クロロプロピル)マロン酸ジエチル(350mg)を加えて約60℃で一夜反応した。反応液に酢酸エチル(300mL)を加えて水、飽和食塩水で順次洗浄した。酢酸エチル層を硫酸マグネシウムで脱水後、減圧濃縮した。残渣をシリカゲルカラム(クロロホルム)で精製して[3−[[6−(2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]プロピル]プロパン二酸ジエチルエステル(299mg,Y=52%)を得た。
[3−[[6−(2−ベンゾオキサゾリル)−2−ナフタレニル]オキシ]プロピル]プロパン二酸ジエチルエステル(299mg)にメタノール(50mL)、30%水酸化ナトリウム水溶液(1mL)を加えて室温で一夜反応した。反応液を減圧濃縮し、残渣に水(50mL)を加えて溶解後、希塩酸を加えて酸析した。析出した結晶をろ取、乾燥して目的化合物(174mg,Y=66%)を得た。
[3−[[6−[4−[(2−フルオロフェニル)メトキシ]−6−フェニル−2−ピリミジニル]−2−ナフタレニル]オキシ]プロピル]プロパン二酸の製造:
DMF(10ml)中、6−[4−[(2−フルオロフェニル)メトキシ]−6−フェニル−2−ピリミジニル]−2−ナフタレノール(422mg)に炭酸カリウム(276mg)、(3−クロロプロピル)マロン酸ジエチル(284mg)を加え、80℃下20時間撹拌した。反応液をろ過し、ろ液を減圧濃縮した。残渣をシリカゲルカラム(トルエン−クロロホルム)に付し、油状の[3−[[6−[4−[(2−フルオロフェニル)メトキシ]−6−フェニル−2−ピリミジニル]−2−ナフタレニル]オキシ]プロピル]プロパン二酸ジエチルエステルを得た。エタノール(10ml)中、得られたエステルに1規定水酸化ナトリウム(2.5ml)を加え、還流下1時間加水分解した。加水分解液を冷却し、析出物をろ取した。得られた結晶を水(50ml)に加温溶解し、ろ過した後、ろ液を凍結乾燥し、白色固体の化合物[3−[[6−[4−[(2−フルオロフェニル)メトキシ]−6−フェニル−2−ピリミジニル]−2−ナフタレニル]オキシ]プロピル]プロパン二酸・2Na(171mg)を得た。得られた結晶を水に溶解後、0.1規定塩酸で酸析し、目的化合物の白色結晶を得た。
錠剤:
本発明のプロパン二酸誘導体 10.0g
乳糖 9.0g
ヒドロキシプロピルセルロース 2.0g
結晶セルロース 7.7g
ステアリン酸マグネシウム 0.3g
タルク 1.0g
以上の成分を用いて常法により、本発明のプロパン二酸誘導体100mgを含有する錠剤とする。
PAI−1阻害活性:
PAI−1阻害活性は、国際公開第WO04/011442号パンフレット、国際公開第WO04/10996号パンフレット、特開2004−250401号公報などに記載の方法に従い、合成基質S−2288を用いて測定する事が出来る。
PAI−1阻害活性値の代表例を表12に示す。
がん抑制試験:
(1)試験方法
5週齢オスMinマウス(日本クレア)を購入し、1週間の基礎飼料(AIN−76A)投与後、被験物質を100 ppm餌に混ぜて投与した。また、そのwild−typeマウスにも同等量の被験物質を餌に混ぜて投与した。体重と摂餌量は毎週測定した。マウスは15週齢にて麻酔下にて屠殺し、主要臓器(脾臓及び心臓)の重量測定を行った。小腸及び大腸は洗浄後、縦方向に開きホルマリン固定した。小腸及び大腸の腸管ポリープ数及び大きさを実体顕微鏡下にて測定した。
化合物20を用いて実施した試験の結果を図1、図2に示す。図1、図2より、以下のことが判明した。
1.腸管ポリープ生成に伴う出血による貧血の指標である脾臓の重量及び心臓の重量を測定することによる評価:化合物20投与群では有意に脾臓の重量及び心臓の重量が減少していた。
2.マウス当たりの腸管ポリープ数:小腸の近位部において特に強く抑制されており、総ポリープ数は約66%にまで減少した。
3.ポリープサイズの分布においては、全体的にサイズの減少が認められた。特に1mm径以下のポリープサイズに有意な減少が認められた。
以上の試験結果より、本発明のプロパン二酸誘導体である、PAI−1阻害活性を有する化合物に消化管ポリープの発生、進展を抑制する効力がある事が確認された。
Claims (4)
- 下記式(4)
で表されるプロパン二酸誘導体、その非毒性塩又は溶媒和物を有効成分として含有する、消化管ポリープの予防もしくは治療薬。 - 下記式(5)
- 下記の化合物、その非毒性塩又は溶媒和物を有効成分として含有する、請求項1又は2のいずれかの消化管ポリープの予防もしくは治療薬。
[5−[[6−[5−(1,1−ジメチルエチル)−2−ベンゾオキサゾリル]−2−ナフタレニル]オキシ]ペンチル]プロパン二酸。 - 消化管ポリープの予防もしくは治療薬を製造する為の請求項1から3のいずれかに記載のプロパン二酸誘導体、その非毒性塩又は溶媒和物の使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/310977 WO2007138705A1 (ja) | 2006-06-01 | 2006-06-01 | 発がん抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007138705A1 JPWO2007138705A1 (ja) | 2009-10-01 |
JP4417424B2 true JP4417424B2 (ja) | 2010-02-17 |
Family
ID=38778233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008517764A Expired - Fee Related JP4417424B2 (ja) | 2006-06-01 | 2006-06-01 | 発がん抑制剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090118314A1 (ja) |
EP (1) | EP2022500A4 (ja) |
JP (1) | JP4417424B2 (ja) |
AU (1) | AU2006345660A1 (ja) |
CA (1) | CA2651368A1 (ja) |
WO (1) | WO2007138705A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100035296A1 (en) * | 2007-01-04 | 2010-02-11 | Anat Shirvan | Compounds and methods for detection of cells |
WO2010086964A1 (ja) * | 2009-01-28 | 2010-08-05 | 株式会社 静岡カフェイン工業所 | がん治療のための併用療法 |
JPWO2010137160A1 (ja) * | 2009-05-29 | 2012-11-12 | 株式会社静岡カフェイン工業所 | 肺線維症の予防もしくは治療薬 |
US20120142722A1 (en) * | 2009-06-25 | 2012-06-07 | Ilan Ziv | Conjugates of cytotoxic drugs |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW225528B (ja) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
DK85193D0 (da) * | 1993-07-16 | 1993-07-16 | Cancerforskningsfondet Af 1989 | Suppression of inhibitors |
TW321649B (ja) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
CA2207083A1 (en) * | 1996-07-15 | 1998-01-15 | Brian William Grinnell | Benzothiophene compounds, and uses and formulations thereof |
JP2004011442A (ja) | 2002-06-04 | 2004-01-15 | Nissan Motor Co Ltd | 内燃機関の吸気装置 |
JP2004010996A (ja) | 2002-06-10 | 2004-01-15 | Jfe Steel Kk | 低温靭性に優れた耐摩耗鋼およびその製造方法 |
WO2004010996A1 (ja) | 2002-07-29 | 2004-02-05 | Shizuoka Coffein Co., Ltd. | 1,3アゾール誘導体及び同誘導体を含む血栓症治療のための医薬組成物 |
JP4322208B2 (ja) | 2002-07-29 | 2009-08-26 | 株式会社静岡カフェイン工業所 | ピリミジン誘導体 |
WO2004052856A1 (en) * | 2002-12-10 | 2004-06-24 | Wyeth | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
JP4390460B2 (ja) | 2003-02-21 | 2009-12-24 | 株式会社静岡カフェイン工業所 | オキサゾール誘導体 |
JP4334508B2 (ja) | 2005-06-22 | 2009-09-30 | 株式会社静岡カフェイン工業所 | 1,3−アゾール誘導体 |
-
2006
- 2006-06-01 JP JP2008517764A patent/JP4417424B2/ja not_active Expired - Fee Related
- 2006-06-01 US US12/300,270 patent/US20090118314A1/en not_active Abandoned
- 2006-06-01 CA CA002651368A patent/CA2651368A1/en not_active Abandoned
- 2006-06-01 WO PCT/JP2006/310977 patent/WO2007138705A1/ja active Application Filing
- 2006-06-01 AU AU2006345660A patent/AU2006345660A1/en not_active Abandoned
- 2006-06-01 EP EP06747079A patent/EP2022500A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JPWO2007138705A1 (ja) | 2009-10-01 |
EP2022500A4 (en) | 2010-11-24 |
EP2022500A1 (en) | 2009-02-11 |
CA2651368A1 (en) | 2007-12-06 |
US20090118314A1 (en) | 2009-05-07 |
AU2006345660A1 (en) | 2007-12-06 |
WO2007138705A1 (ja) | 2007-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109476642B (zh) | 化合物及其用于降低尿酸水平的用途 | |
JP5898230B2 (ja) | S−ニトロソグルタチオンレダクターゼ阻害薬としての新規な置換二環芳香族化合物 | |
KR102005068B1 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
WO2015102371A1 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
KR20120083492A (ko) | 신규 5-플루오로우라실 유도체 | |
JP4417424B2 (ja) | 発がん抑制剤 | |
WO2021013250A1 (zh) | 杂环酰胺类化合物及其制备方法和应用 | |
EP3680232A1 (en) | NOVEL ANTHRANILIC ACID-BASED COMPOUND, AND Pin1 INHIBITOR, THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES AND THERAPEUTIC AGENT FOR CANCER THAT USE THE SAME | |
WO2016039398A1 (ja) | 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物 | |
CA2960324A1 (en) | Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents | |
CN111777501B (zh) | 咖啡酸苯乙酯类衍生物,其制法和其药物组合物与用途 | |
AU2015207690B2 (en) | Substituted bicyclic heteroaryl compounds as RXR agonists | |
US20170354620A1 (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
WO2015102369A1 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
JP2018515540A (ja) | 乳癌の予防又は治療用の化合物 | |
WO2006102363A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
JP7485311B2 (ja) | がん細胞増殖抑制剤及びがん細胞増殖抑制効果増強剤 | |
BR112020022220A2 (pt) | novo composto e composição farmacêutica compreendendo o mesmo | |
JP4390460B2 (ja) | オキサゾール誘導体 | |
CN108689936B (zh) | 含氮取代基的吲唑类化合物及其作为ido抑制剂的用途 | |
CN107556316B (zh) | 含桥环的咪唑衍生物 | |
JPWO2019031470A1 (ja) | 新規アミド系化合物、並びにそれを用いたPin1阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
WO2006132438A1 (ja) | 1,3-ベンゾチアジノン誘導体およびその用途 | |
CN101648919A (zh) | 3-取代水杨酰胺化合物、及其制法和药物组合物与用途 | |
CN111303161B (zh) | 嘧啶并氮杂环类化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090805 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090908 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091020 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091113 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091125 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4417424 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121204 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121204 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121204 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121204 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121204 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121204 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131204 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |